Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines

被引:469
|
作者
Greish, Khaled [1 ]
机构
[1] Sojo Univ, Fac Pharmaceut Sci, Lab Microbiol & Oncol, Kumamoto 8600082, Japan
基金
日本学术振兴会;
关键词
EPR effect; nanomedicines; micelles; targeted anticancer therapy; macromolecular drugs;
D O I
10.1080/10611860701539584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Over the past two decades cancer has ascended the causes of human death to be number one or two in many nations world wide. A major limitation inherent to most conventional anticancer chemotherapeutic agents is their lack of tumor selectivity. One way to achieve selective drug targeting to solid tumors is to exploit abnormalities of tumor vasculature, namely, hypervascularisation; aberrant vascular architecture; extensive production of vascular permeability factors stimulating extravasation within tumor tissues, and lack of lymphatic drainage. Maeda and his colleagues have extensively studied tumor vascular abnormalities in terms of active and selective delivery of anticancer drugs to tumor tissues, notably defining the enhanced permeability and retention effect (EPR effect) of macromolecular drugs in solid tumors. Due to their large molecular size, nanosized macromolecular anticancer drugs administered intravenously (i.v.) escape renal clearance. Often they can not penetrate the tight enclothelial junctions of normal blood vessels, but they can extravasate in tumour vasculature and become trapped in the tumor vicinity. With time the tumor concentration will build up reaching several folds higher than that of the plasma due to lack of efficient lymphatic drainage in solid tumor; an ideal application for EPR-based selective anticancer drug delivery. Establishing this principle hastened development of various polymer conjugates and polymeric micelles as well as multifunctional nanoparticles for targeted cancer chemotherapy. Indeed this selective high local concentration of nanosized anticancer drugs in tumor tissues has proven superior in therapeutic effect with minimal side effects in both preclinical and clinical settings. In this review the mechanisms and factors involved in the EPR effect, as well as the uniqueness of nanoscale drugs for tumor targeting through EPR effect, will be discussed in detail.
引用
收藏
页码:457 / 464
页数:8
相关论文
共 50 条
  • [41] A Retrospective 30Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic TherapyProblems, Solutions, and Prospects
    Maeda, Hiroshi
    Tsukigawa, Kenji
    Fang, Jun
    MICROCIRCULATION, 2016, 23 (03) : 173 - 182
  • [42] Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System
    Heneweer, Carola
    Holland, Jason P.
    Divilov, Vadim
    Carlin, Sean
    Lewis, Jason S.
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (04) : 625 - 633
  • [43] Tumor-targeted taxane: PK evidence for an enhanced permeability and retention effect with paclitaxel poliglumex (CT-2103)
    Bernareggi, Alberto
    Oldham, Fred
    Barone, Carlo
    ANNALS OF ONCOLOGY, 2004, 15 : 103 - 103
  • [44] DRUG DELIVERY SYSTEMS IMPROVING CHEMICAL AND PHYSICAL PROPERTIES OF ANTICANCER DRUGS CURRENTLY INVESTIGATED FOR TREATMENT OF SOLID TUMORS
    Aleksandrowicz, R.
    Taciak, B.
    Krol, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2017, 68 (02): : 165 - 174
  • [45] Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors
    Nagamitsu, Akinori
    Greish, Khaled
    Maeda, Hiroshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (11) : 756 - 766
  • [46] Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect
    Yoshikawa, Takuma
    Mori, Yukina
    Feng, Haitao
    Khanh Quoc Phan
    Kishimura, Akihiro
    Kang, Jeong-Hun
    Mori, Takeshi
    Katayama, Yoshiki
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 565 : 481 - 487
  • [47] Hypoxia-responsive block copolymer radiosensitizers as anticancer drug nanocarriers for enhanced chemoradiotherapy of bulky solid tumors
    Yin, Wei
    Qiang, Ming
    Ke, Wendong
    Han, Yu
    Mukerabigwi, Jean Felix
    Ge, Zhishen
    BIOMATERIALS, 2018, 181 : 360 - 371
  • [48] Hemoglobin-based Oxygen Carriers Combined with Anticancer Drugs May Enhance Sensitivity of Radiotherapy and Chemotherapy to Solid Tumors
    Wu, Wei
    Yang, Qian
    Li, Tao
    Zhang, Pu
    Zhou, Ronghua
    Yang, Chengmin
    ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY, 2009, 37 (04): : 163 - 165
  • [49] Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution
    Park, Hyung Soon
    Lim, Sun Min
    Kim, Sora
    Kim, Sangwoo
    Kim, Hye Ryun
    Kwack, KyuBum
    Lee, Min Goo
    Kim, Joo-Hang
    Moon, Yong Wha
    PLOS ONE, 2016, 11 (04):
  • [50] Starlike vs. Classic Macromolecular Prodrugs: Two Different Antibody-Targeted HPMA Copolymers of Doxorubicin Studied in Vitro and in Vivo as Potential Anticancer Drugs
    Markéta Jelínková
    Jiří Strohalm
    Tomáš Etrych
    Karel Ulbrich
    Blanka Říhová
    Pharmaceutical Research, 2003, 20 : 1558 - 1564